VHB 937
Alternative Names: VHB-937Latest Information Update: 13 Feb 2026
At a glance
- Originator Novartis; Novartis Institutes for BioMedical Research
- Class Anti-inflammatories; Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action TREM2 protein-stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Amyotrophic lateral sclerosis
- Preclinical Inflammation; Multiple sclerosis; Neurodegenerative disorders
Most Recent Events
- 31 Dec 2025 Novartis intends to file regulatory applications for the approval of VHB 937 in Alzheimer's disease and Amyotrophic lateral sclerosis in or after 2029 (Novartis pipeline, December 2025)
- 24 Sep 2025 Preclinical trials in Inflammation in USA (IV), prior to September 2025
- 24 Sep 2025 Preclinical trials in Multiple sclerosis in USA (IV), prior to September 2025